Skip to main content
Erschienen in: BMC Infectious Diseases 1/2003

Open Access 01.12.2003 | Research article

Risk factors for high anti-HHV-8 antibody titers (≥1:51,200) in black, HIV-1 negative South African cancer patients: a case control study

verfasst von: Janet M Wojcicki, Rob Newton, Margaret I Urban, Lara Stein, Martin Hale, Moosa Patel, Paul Ruff, Ranjan Sur, Dimitra Bourboulia, Freddy Sitas

Erschienen in: BMC Infectious Diseases | Ausgabe 1/2003

Abstract

Background

Infection with human herpesvirus 8 (HHV-8), also known as Kaposi's sarcoma-associated herpesvirus (KSHV), is the necessary causal agent in the development of Kaposi's sarcoma (KS). Infection with HIV-1, male gender and older age all increase risk for KS. However, the geographic distribution of HHV-8 and KS both prior to the HIV/AIDS epidemic and with HIV/AIDS suggest the presence of an additional co-factor in the development of KS.

Methods

Between January 1994 and October 1997, we interviewed 2576 black in-patients with cancer in Johannesburg and Soweto, South Africa. Blood was tested for antibodies against HIV-1 and HHV-8 and the study was restricted to 2191 HIV-1 negative patients. Antibodies against the latent nuclear antigen of HHV-8 encoded by orf73 were detected with an indirect immunofluorescence assay. We examined the relationship between high anti-HHV-8 antibody titers (≥1:51,200) and sociodemographic and behavioral factors using unconditional logistic regression models. Variables that were significant at p = 0.10 were included in multivariate analysis.

Results

Of the 2191 HIV-1 negative patients who did not have Kaposi's sarcoma, 854 (39.0%) were positive for antibodies against HHV-8 according to the immunofluorescent assay. Among those seropositive for HHV-8, 530 (62.1%) had low titers (1:200), 227 (26.6%) had medium titers (1:51,200) and 97 (11.4%) had highest titers (1:204,800). Among the 2191 HIV-1 negative patients, the prevalence of high anti-HHV-8 antibody titers (≥1:51,200) was independently associated with increasing age (ptrend = 0.04), having a marital status of separated or divorced (p = 0.003), using wood, coal or charcoal as fuel for cooking 20 years ago instead of electricity (p = 0.02) and consuming traditional maize beer more than one time a week (p = 0.02; p-trend for increasing consumption = 0.05) although this may be due to chance given the large number of predictors considered in this analysis.

Conclusions

Among HIV-negative subjects, patients with high anti-HHV-8 antibody titers are characterized by older age. Other associations that may be factors in the development of high anti-HHV-8 titers include exposure to poverty or a low socioeconomic status environment and consumption of traditional maize beer. The relationship between these variables and high anti-HHV-8 titers requires further, prospective study.
Hinweise

List of competing interests

None declared.

Background

Human herpesvirus 8 (HHV-8, also known as Kaposi's sarcoma-associated herpesvirus) is understood to be the necessary, causal agent in the development of Kaposi's Sarcoma (KS) [13]. HHV-8 has been detected in the lesions of nearly all patients with Kaposi's sarcoma [4, 5] and it predicts the development of Kaposi's sarcoma when found in the blood [3, 6].
Not all individuals infected with HHV-8 develop KS suggesting the presence of a co-factor in the development of the malignancy [7, 8]. HIV infection, other immunosuppression, male gender and older age all increase risk [9, 10]. To explain the geographical variation in KS incidence world-wide, researchers have proposed additional co-factors. In particular, researchers have suggested that infection with HHV-8 later in life, high socioeconomic status and/or exposure to substances in the water or soil may be potential co-factors increasing risk for KS in adulthood [1113]. High anti-HHV-8 antibody titers have been correlated with high HHV-8 viral load and increased risk for development of KS [1416], but risk factors other than age and length of infection for elevated titers have not been determined [17, 18]. The aim of our study was to identify risk factors for high titers to HHV-8 (≥1:51,200) as a means to better understand risk factors for Kaposi's sarcoma among HIV-seronegative, black adults in South Africa. Using a database of information on over 2000 HIV-1 negative black, South African hospitalized cancer patients, we conducted a case control study of risk factors for high titers to HHV-8 (≥1:51,200) using patients with high titers as cases and HHV-8 infected patients with low titers as controls (median titer 1:200).

Methods

Study participants

The participants included in our analyses were part of a large epidemiologic study conducted by researchers from the South African National Cancer Registry and the Department of Medicine of the University of the Witwatersrand, in collaboration with investigators in the United Kingdom as described elsewhere [14]. The study was conducted between January 1994 and October 1997 at three Johannesburg hospitals (Chris Hani-Baragwanath, Hillbrow and Johannesburg). Trained nurses interviewed 2576 black inpatients with cancer using a questionnaire in the language of the patient (most commonly Zulu or Sotho).

Serologic Tests for HHV-8 and HIV-1

The serum samples were shipped by air on dry ice to the Institute of Cancer Research in London for HHV-8 testing. Details of the testing procedure are described elsewhere [14]. Briefly, a B-cell lymphoma (primary effusion lymphoma) cell line, BCP-1, infected with HHV-8 but not Epstein Barr virus (EBV) was used for an indirect immunofluorescence assay to detect IgG antibodies against HHV-8 antigen. All assays were examined by a single observer [2, 19]. Slides were screened by ultra-violet microscopy for the latent nuclear antigen of HHV-8 encoded by orf73 [2, 2024]. Serum samples that were positive for antibodies against HHV-8 by the immunofluorescence assay were scored as low (median titers were 1:200), medium (1:51,200) or high (1:204,800) according to the intensity of the fluorescent signal. These scores correlated well with intensity of fluorescence as measured by fluorescence-activated cell sorter (FACS) analysis described in detail in Sitas et al. 1999.

Statistical Analysis

Within this group of 2576 black inpatients interviewed between 1994–1997, serum samples from 2329 (90 percent) were tested for antibodies to HHV-8. We restricted analyses to those patients who were HIV-1 negative and without KS. A total number of 2191 HIV-1 negative patients without KS who were tested for HHV-8 form the basis for the analysis presented in this paper. We decided to restrict the study to HIV-1 negative patients so as to remove the confounding between level of immunosuppression and high HHV-8 titers or risk of Kaposi's sarcoma [25]. Since the factors influencing high titers to HHV-8 are not known, we initially examined the relation between high antibody titers to HHV-8 (≥1:51,200) and all questions from our questionnaire including age, sex, education, place of birth, place of residence, parity, number of lifetime sexual partners, history of contraceptive use for women, frequency and type of alcohol consumption, use and frequency of tobacco and other lifestyle variables such as fuel use for cooking and heating and building materials used in house construction. Odds ratios were calculated by unconditional logistic regression adjusting for age group (<35, 35 to 44, 45 to 54, 55 to 64, or ≥ 65) and sex as indicated using STATA [26]. All p-values are 2-sided. Numbers of cases and controls in the tables do not always add up to the total because of missing values.
Factors that were significant in bivariate analyses at p= 0.10 were included in a multivariate logistic regression analysis, to identify which factors, if any, were independently associated with high HHV-8 titers. Goodness of fit was assessed by the Hosmer-Lemeshow test [27]. The variable "use of fuel for warming 20 years ago" was not considered in the multivariate model because it was collinear with the variable "use of fuel for cooking 20 years ago." The variable "frequency of sorghum beer consumption" was also not considered in the multivariate model because it was collinear with the variable "frequency of traditional maize beer consumption." We examined the confounding effect of other variables. In general, confounding was defined when inclusion of a variable in the multivariate model resulted in a change of more than 15 percent in odds ratios of factors already present in the model. Variables that had a considerable number of "missings" were modeled in our analysis with a separate "missing values" category.

Results

High antibody titers (≥1:51,200) against HHV-8 in Relation to Demographic and Behavioral Factors

Of the 2191 HIV-1 negative samples who did not have Kaposi's sarcoma, 854 (39.0%) were positive for antibodies against HHV-8 according to the immunofluorescent assay. Among those seropositive for HHV-8, 530 (62.1%) have low titers (1:200), 227 (26.6%) have medium titers (1:51,200) and 97 (11.4%) have highest titers (1:204,800). Table 1 provides some socio-demographic information about our sample in relation to HHV-8 infection and level of anti-HHV-8 antibody titers.
Table 1
Sociodemographic Characteristics of Participants in relation to HHV-8 seropositivity and anti-HHV-8 titer level.
 
Total
No. HHV-8 neg (%)
No. HHV-8 pos (%)
No. low titer (%)
No. med. titer (%)
No. high titer (%)
TOTAL
2191
1337 (61.0)
854 (39.0)
530 (62.1)
227 (26.6)
97 (11.4)
Sex
      
Male
857 (39.1)
522 (60.9)
335 (39.1)
207 (61.8)
85 (25.4)
43 (12.8)
Female
1334 (60.9)
815 (61.1)
519 (38.9)
323 (62.2)
142 (27.4)
54 (10.4)
Age group
      
<35
205 (9.4)
157 (76.6)
48 (23.4)
38(79.2)
9(18.8)
1 (2.1)
35–44
333 (15.2)
220 (66.1)
113 (33.9)
77 (68.1)
31(27.4)
5 (4.4)
45–54
533 (24.4)
343 (64.4)
190 (35.7)
121 (63.7)
51 (26.8)
18(9.5)
55–64
539 (24.6)
319 (59.2)
220 (40.8)
133 (60.5)
60(27.3)
27(12.3)
≥ 65
578 (26.4)
297 (51.4)
281(48.6)
159 (56.6)
76(27.1)
46(16.4)
Marital status
      
Single
527 (24.1)
352 (66.8)
175 (33.2)
124 (70.9)
42 (24.0)
9 (5.1)
Married
1161 (53.1)
703 (60.6)
458 (39.5)
292 (63.8)
115 (25.1)
51 (11.1)
Widowed
344 (15.7)
182 (52.9)
162 (47.1)
87 (53.7)
52 (32.1)
23 (14.2)
Divorced
153 (7.0)
95 (62.1)
58 (37.9)
27 (46.6)
18 (31.0)
13 (22.4)
Separated
      
No. of lifetime sexual Partners
      
0–2
455 (22.6)
288(63.3)
167 (36.7)
103 (61.7)
47 (28.1)
17 (10.2)
3–4
1051 (52.2)
628(59.8)
423 (40.3)
267 (63.1)
111 (26.2)
45 (10.6)
≥ 5
508 (25.2)
306(60.2)
202 (39.8)
123 (60.9)
51 (25.3)
28 (13.9)
Education
      
None
581 (26.7)
310 (53.4)
271 (46.6)
153 (56.5)
82 (30.3)
36 (13.3)
1–5 years
878 (40.3)
539 (61.4)
339 (38.6)
219 (64.6)
83 (24.5)
37 (10.9)
≥ 6 years
719 (33.0)
479 (66.6)
240 (33.4)
156 (65.0)
60 (25.0)
24 (10.0)
Occupation
      
White-collar
270 (13.5)
181 (67.0)
89 (33.0)
52 (58.4)
25 (28.1)
12 (13.5)
Non-active
237 (11.8)
138 (58.2)
99 (41.8)
68 (68.7)
21 (21.2)
10 (10.1)
Farming
97 (4.8)
56 (57.7)
41 (42.3)
27 (65.9)
7 (17.1)
7 (17.1)
Industry
559 (27.9)
378 (67.6)
181 (32.4)
109 (60.2)
47 (26.0)
25 (13.8)
Domestic
756 (37.7)
424 (56.1)
332 (43.9)
202 (60.8)
97 (29.2)
33 (9.9)
Unspecified
88 (4.4)
56 (63.6)
32 (36.4)
17 (53.1)
10 (31.3)
5 (15.6)
Place of birth
      
Rural
1245 (59.0)
729 (58.6)
516 (41.5)
324 (62.8)
133 (25.8)
59 (11.4)
Urban
866 (41.0)
553 (63.9)
313 (36.1)
188 (60.1)
89 (28.4)
36 (11.5)
Place of residence
      
Urban
1698 (79.6)
1038 (80.0)
259 (20.0)
413 (62.6)
170 (25.8)
77 (11.7)
Rural
435 (20.4)
660 (79.0)
176 (21.1)
103 (58.5)
54 (30.7)
19 (10.8)
The prevalence of high titers did not differ significantly by sex being 38.2% (128/335) in men and 37.8% (196/518) in women (p = 0.62). However, the prevalence of high titers increased linearly with age from 20.8% in those under 35 years (10/48), 31.9% in those 35–44 (36/113), 36.3% for ages 45–54 (69/190), 39.6% for ages 55–64 (87/220) to 43.4% (122/281) in those 65 years or older (p-trend =0.001). Anti-HHV-8 high antibody titers were not associated with educational status (p = 0.30), place of birth (p = 0.10), province of birth (p = 0.36), place of residence (p = 0.18) or province of residence (p = 0.37) (Table 2).
Table 2
Socio-demographic factors in relation to the risk of high anti-HHV-8 titers (≥ 1:51, 200) *
Characteristic
high titer/total pos (%)¥
aOR * 95%CI
Sex
  
Male§
128/335 (38.2)
1.0
Female
196/518 (37.8)
1.08 (0.80–1.45)
Test of Homogeneity
 
χ2 = 0.25, p = 0.62
Age group
  
<35§
10/48 (20.8)
1.0
35–44
36/113 (31.9)
1.76 (0.79–3.93)
45–54
69/190 (36.3)
2.16 (1.01–2.41)
55–64
87/220 (39.6)
2.48 (1.18–5.25)
≥ 65
122/281 (43.4)
2.96 (1.42–6.19)
Test for trend
 
χ2 = 11.16, p = 0.001
Educational level
  
None§
118/270 (43.7)
1.0
1–5
120/339 (35.4)
0.75 (0.54–1.05)
≥ 6 years
84/240 (35.0)
0.83 (0.57–1.21)
Test for trend
 
χ2 = 1.08, p = 0.30
Place of birth
  
Rural §
192/516 (37.2)
1.0
Urban
125/312 (40.1)
1.29 (0.95–1.74)
Test of Homogeneity
 
χ2 = 2.73, p = 0.10
Place of birth
  
Other§
212/558 (38.0)
1.0
Gauteng
112/290 (38.6)
1.16 (0.85–1.56)
Test of Homogeneity
 
χ2 = 0.84, p = 0.36
Place of residence
  
Urban§
247/659 (37.5)
1.0
Rural
73/176 (41.5)
1.26 (0.89–1.78)
Test of Homogeneity
 
χ2 = 1.84, p = 0.18
Place of residence
  
Gauteng§
243/648 (37.5)
1.0
Other
81/205 (39.5)
1.15 (0.83–1.60)
Test of Homogeneity
 
χ2 = 0.82, p = 0.37
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 and sex. ¥ Data were not available for all patients for all variables. § These patients served as the reference group. All values were calculated with the χ2 test with 1 df unless noted otherwise.
The results for variables characterizing wealth in South Africa are displayed in Table 3. A few of the factors associated with poverty were linked with an increased risk of high anti-HHV-8 antibody titers. The risk of high anti-HHV-8 antibody titers was increased in those who lived in structures that were constructed out of tin, mud, wood or other building materials as opposed to brick (OR = 1.49, 95%CI 1.01–2.21; p = 0.04). The risk of high anti-HHV-8 antibody titers was lower in those who had used electricity 20 years ago both for fuel to cook food and also as a means to heat their homes (for warmth) (OR = 0.44, 95%CI 0.25–0.78; p = 0.005 for cooking; OR = 0.43 95%CI 0.25–0.73; p = 0.004 for warmth). Similarly, those individuals who reported that their eyes had watered in their homes as a result of excessive smoke exposure for more than 5 years (potentially related to the use of coal or wood for fuel) also had an increased risk of having high anti-HHV-8 titers (OR = 1.56, 95%CI 1.16–2.08; p = 0.003). Other variables associated with socioeconomic status (occupational status, cooking food indoors versus outdoors, and employed/unemployed) were not associated with high HHV-8 titers.
Table 3
Some factors characterizing wealth in relation to high anti-HHV-8 antibody titers*
Characteristic
high titer/total pos (%)¥
aOR * 95%CI
Walls of home (building materials used)
  
Brick§
268/727 (36.9)
1.0
Other
56/127 (44.1)
1.49 (1.01–2.21)
Test of Homogeneity
 
χ2 = 4.04, p = 0.04
Location for cooking food now
  
Inside home§
308/808 (38.1)
1.0
Outside home
16/45 (35.6)
0.92 (0.49–1.73)
Test of Homogeneity
 
χ2 = 0.06, p = 0.80
Type of fuel used for cooking food now
  
Electricity §
229/597 (38.4)
1.0
Other
95/256 (37.1)
0.99 (0.73–1.34)
Test of Homogeneity
 
χ2 = 0.01, p = 0.93
Type of fuel used for heating now
  
Electricity§
228/595 (38.3)
1.0
Other
96/258 (37.2)
1.00 (0.73–1.35)
Test of Homogeneity
 
χ2 = 0.00, p = 0.98
Location for cooking food 20 years ago
  
Inside§
282/749 (37.7)
1.0
Outside
41/108 (39.8)
1.10 (0.72–1.69)
Test of Homogeneity
 
χ2 = 0.20, p = 0.65
Type of fuel used for cooking food 20 years ago
  
Other§
306/771 (39.7)
1.0
Electricity
17/81 (21.0)
0.44 (0.25–0.78)
Test of Homogeneity
 
χ2 = 8.08, p = 0.005
Type of fuel used for heating 20 years ago
  
Other§
307/773 (39.7)
1.0
Electricity
16/79 (20.3)
0.43 (0.25–0.73)
Test of Homogeneity
 
χ2 = 8.5, p = 0.004
Eyes watering in house from smoke
  
No§
142/432 (32.9)
1.0
Yes/
160/365 (43.8)
1.56 (1.16–2.08)
(More than 5 Years)
  
Test of Homogeneity
 
χ2 = 8.82, p = 0.003
Working Now
  
No§
261/673 (38.7)
1.0
Yes
54/167 (32.3)
0.85 (0.58–1.26)
Test of Homogeneity
 
χ2 = 0.72, p = 0.39
On pension/disability
  
No§
153/449 (34.1)
1.0
Yes
163/392 (41.6)
1.01 (0.67–1.52)
Test of Homogeneity
 
χ2 = 0.00, p = 0.97
Occupational status
  
White-collar§
37/89 (41.6)
1.0
Non-active
31/99 (31.3)
0.71 (0.38–1.33)
Farming
14/41 (34.2)
0.63 (0.29–1.38)
Industry
72/181 (39.8)
0.85 (0.50–1.44)
Domestic
130/331 (39.3)
0.85 (0.52–1.41)
Unspecified
15/32 (46.9)
1.53 (0.65–3.59)
Test of Homogeneity
 
χ2 (5df) = 4.49, p = 0.48
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 and sex. ¥ Data were not available for all patients for all variables. § These patients served as the reference group. All values were calculated with the χ2 test with 1 df unless noted otherwise.
Table 4 displays the results for variables characterizing smoking and alcohol use in this population. We did not find any association between being a current or past smoker, the use of snuff, consumption of commercial beers, commercial spirits, wine and increased risk for high titers. We did find an increased risk of high titers among those who consumed traditional maize and sorghum beers with increased risk for those consuming maize beer more than once a week (OR = 5.10, 95%CI 1.64–15.87) and for those consuming most days (OR = 3.07, 95%CI 1.19–7.90; p-trend = 0.002). Among those who drink traditional sorghum beer more than once a week risk was also elevated (OR = 2.46, 95%CI 1.08–5.64; p-trend = 0.04). Similarly, consumption of homemade spirits was also associated with an increased risk of having high titers with increased risk for those consuming homemade spirits less than one time a week (OR = 2.26, 95%CI 1.03–5.00; p-trend = 0.02).
Table 4
Factors related to smoking and alcohol use in relation to high anti-HHV-8 antibody titers*
Characteristic
High titer/total pos (%)¥
aOR * 95%CI
Smoke cigarettes/pipes
  
No§
179/486 (36.8)
1.0
Past
96/233 (41.2)
1.12 (0.77–1.62)
Yes
46/128 (35.9)
1.00 (0.64–1.57)
Test of Homogeneity
 
χ2 (2df) = 0.43, p = 0.80
Use of snuff
  
No§
255/691 (36.9)
1.0
Past
22/57 (38.6)
0.97 (0.54–1.71)
Current
47/101 (46.5)
1.48 (0.95–2.30)
Test of Homogeneity
 
χ2 (2df) = 2.56, p = 0.11
Consumption of maize beer
  
Never§
277/761 (36.4)
1.0
Less than 1× week
18/50 (36.0)
0.92 (0.51–1.69)
More than 1× week
13/17 (76.5)
5.10 (1.64–15.87)
Most days
13/20 (65.0)
3.07 (1.19–7.90)
Test for Trend
 
χ2 = 9.49, p = 0.002
Consumption of sorghum beer
  
Never§
250/692 (36.1)
1.0
Less than 1× week
47/116 (40.5)
1.12 (0.74–1.70)
More than 1× week
15/25 (60.0)
2.46 (1.08–5.64)
Most days
7/13 (53.9)
1.93 (0.64–5.86)
Test for Trend
 
χ2 = 4.29, p = 0.04
Consumption of other homemade beer
  
Never§
249/636 (39.2)
1.0
Less than 1× week
43/151 (28.5)
0.52 (0.34–0.78)
More than 1× week
18/38 (47.4)
1.18 (0.60–2.31)
Most days
7/18 (38.9)
0.91 (0.34–2.41)
Test for Trend
 
χ2 = 1.46, p = 0.23
Consumption of homemade spirits
  
Never§
284/776 (36.6)
1.0
Less than 1× week
15/27 (55.6)
2.26 (1.03–5.00)
More than 1× week
4/8 (50.0)
1.60 (0.39–6.53)
Most days
13/25 (52.0)
2.05 (0.91–4.60)
Test for Trend
 
χ2 = 5.11, p = 0.02
Consumption of commercial beer
  
Never§
187/508 (36.8)
1.0
Less than 1× week
21/48 (43.8)
1.32 (0.72–2.43)
More than 1× week
38/81 (46.9)
1.35 (0.83–2.21)
Most days
74/211 (35.1)
0.85 (0.58–1.250
Test for Trend
 
χ2 = 0.24=, p = 0.63
Consumption of commercial spirits
  
Never§
257/680 (37.8)
1.0
Less than 1× week
29/82 (35.4)
0.85 (0.52–1.39)
More than 1× week
12/39 (30.8)
0.68 (0.33–1.41)
Most days
22/45 (48.9)
1.59 (0.85–2.99)
Test for Trend
 
χ2 = 0.37, p = 0.54
Consumption of wine
  
Never§
278/733 (37.9)
1.0
Less than 1× week
23/68 (33.8)
0.83 (0.49–1.41)
More than 1× week
3/6 (50.0)
1.58 (0.31–8.01)
Most days
13/27 (48.2)
1.63 (0.75–3.56)
Test for Trend
 
χ2 = 0.90, p = 0.34
Consumption of any alcohol
  
No§
162/432 (37.5)
1.0
Yes
159/416 (38.2)
0.94 (0.69–1.29)
Test of Homogeneity
 
χ2= 0.13, p = 0.72
Consumption of any maize or sorghum traditional beers
  
No§
245/682 (35.9)
1.0
Yes
75/166 (45.2)
1.37 (0.95–1.97)
Test of Homogeneity
 
χ2 = 2.85, p = 0.09
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 and sex. ¥ Data were not available for all patients for all variables. § These patients served as the reference group. All values were calculated with the χ2 test with 1 df unless noted otherwise.
We analyzed consumption of alcoholic beverages dichotomizing study participants into non-drinkers and drinkers and found no association between being a drinker of alcoholic beverages and increased risk for high titers. However, dichotomizing participants into those who drink maize and/or sorghum beers with those who do not, the results were marginally significant with drinkers at marginally increased risk (OR 1.37, 95%CI 0.95–1.97; p = 0.09). In South Africa, sorghum beer is often supplemented with maize as a filler as it is cheaper; as maize will supplement sorghum beers, we thought it was necessary to look at the combined group of maize and sorghum to indicate overall exposure to maize.
In Table 5, we looked at associations between markers of sexual activity and reproductive risk factors and high anti-HHV-8 titers. The only factor that had any statistical significance for high anti-HHV-8 titers was marital status with those individuals who were separated/divorced having increased risk in comparison with unmarried individuals (OR = 2.44, 95%CI 1.30–4.58; p = 0.01). We did not find any associations with number of sexual partners (p-trend = 0.54). We also did not find any associations between the various reproductive risk factors including age at menarche, parity, use of oral and injectable contraceptives and risk for high HHV-8 titers.
Table 5
Factors related to sexual exposures and reproduction in relation to high anti-HHV-8 antibody titers
 
high titer/total pos (%)¥
aOR * 95%CI
Number of lifetime husbands/wives
  
0–1§
247/633 (39.0)
1.0
≥ 2
20/45 (44.4)
1.26 (0.68–2.35)
Test for Trend
 
χ2 = 0.55, p = 0.46
Marital status
  
Single§
51/175 (29.1)
1.0
Married
166/458 (36.2)
1.11 (0.73–1.69)
Widowed
75/162 (46.3)
1.54 (0.92–2.59)
Separated/Divorced
31/57 (54.4)
2.44 (1.30–4.58)
Test of Homogeneity (3 df)
 
χ2 = 10.6, p = 0.01
Number of lifetime sexual partners
  
0–2§
64/166 (38.6)
1.0
3–4
156/423 (36.9)
0.94 (0.65–1.38)
≥ 5
79/202 (39.1)
1.11 (0.71–1.74)
Test for Trend
 
χ2 = 0.37, p = 0.54
Pregnant (in lifetime)
  
Yes§
189/501 (37.7)
1.0
No
8/17 (47.1)
1.65 (0.61–4.49)
Test of Homogeneity
 
χ2 = 0.95, p = 0.33
Times pregnant (in lifetime)
  
1§
11/39 (28.2)
1.0
2–3
57/149 (38.3)
1.69 (0.77–3.69)
4–5
54/142 (38.0)
1.50 (0.68–3.29)
≥ 6
68/173 (39.3)
1.45 (0.67–3.15)
Test for Trend
 
χ2 = 0.03, p = 0.87
Times miscarriage (in lifetime)
  
0§
6/12 (50.0)
1.0
1
37/107 (34.6)
0.56 (0.17–1.89)
≥ 2
39/100 (39.0)
0.61 (0.18–2.06)
Test for Trend
 
χ2 = 0.10, p = 0.73
Parity
  
0–2§
53/140 (37.9)
1.0
3–4
57/174 (32.8)
0.73 (0.45–1.18)
≥ 5
74/176 (42.1)
0.99 (0.62–1.59)
Test for Trend
 
χ2 = 0.00, p = 0.95
Number of children (born alive) (for men)
  
0–1§
10/26 (38.5)
1.0
2–3
29/82 (35.4)
0.80 (0.31–2.06)
4–5
31/80 (38.8)
0.76 (0.29–2.01)
≥ 6
49/126 (38.9)
0.69 (0.26–1.79)
Test for Trend
 
χ2 = 0.50, p = 0.48
Number of mothers and fathers (children)
  
1§
237/608 (39.0)
1.0
≥ 2
67/197 (34.0)
0.82 (0.58–1.16)
Test for Trend
 
χ2 = 1.30, p = 0.25
Age when periods began
  
10–13§
17/39 (43.6)
1.0
14
34/81 (42.0)
0.93 (0.42–2.04)
15
53/166 (31.9)
0.55 (0.27–1.14)
≥ 16
91/227 (40.1)
0.77 (0.38–1.56)
Test for Trend
 
χ2 = 0.46, p = 0.50
Age when periods ended
  
≤ 45§
32/94 (34.0)
1.0
46–49
40/100 (40.0)
1.11(0.60–2.08)
≥ 50
85/198 (42.9)
1.24 (0.69–2.23)
Test for Trend
 
χ2 = 0.74, p = 0.39
Oral contraceptives
  
No§
168/424 (39.6)
1.0
Yes
25/86 (29.1)
0.69 (0.40–1.17)
Test of Homogeneity
 
χ2 = 1.88, p = 0.17
Injectable contraceptives
  
No§
165/425 (38.8)
1.0
Yes
28/87 (32.2)
0.93 (0.55–1.59)
Test of Homogeneity
 
χ2 = 0.07, p = 0.80
* Adjusted for age category < 35, 35–44, 45–54, 55–64, or ≥ 65 sex. ¥ Data were not available for all patients for all variables. § These patients served as the reference group. All values were calculated with the χ2 test with 1 df unless noted otherwise.
Those risk factors from Tables 2–5 that were significantly associated with high anti-HHV-8 antibody titers at the 1% level are summarized in Table 6. After adjustment for age group, sex and each other, 4 variables remained independently associated with high anti-HHV-8 titers. People with high anti-HHV-8 titers were more likely to be older (p-trend = 0.04, OR for ≥ 65 years = 2.38, 95%CI 1.04–5.44; p = 0.04), separated or divorced (OR = 2.73, 95%CI 1.41–5.28; p = 0.003), consuming traditional maize beer more than one time a week (OR = 4.16, 95%CI 1.26–13.80; p = 0.02; p-trend for increasing consumption = 0.05) and were less likely to have used electricity for cooking 20 years ago (OR = 0.50, 95%CI 0.27–0.91; p = 0.02).
Table 6
Risk factors for high anti-HHV-8 antibody titers
 
OR (high titers)
(95%CI) p-value
Age group
  
<35§
1.0
 
35–44
1.64 (0.71–3.77)
0.25
45–54
1.79(0.80–3.98)
0.16
55–64
2.03 (091–4.57)
0.09
≥ 65
2.38 (1.04–5.44)
0.04
Test for trend
 
χ2 = 4.45, p = 0.04
Place of birth
  
Rural§
1.0
 
Urban
1.33 (0.97–1.84)
0.08
Test of Homogeneity
 
χ2 = 3.10, p = 0.08
Material in Walls
  
of Housing
  
Brick§
1.0
 
Other
1.43 (0.94–2.17)
0.09
Test of Homogeneity
 
χ2 = 2.86, p = 0.09
Type of fuel used for cooking
  
20 years Ago
  
Other§
1.0
 
Electricity
0.50 (0.27–0.91)
0.02
Test of Homogeneity
 
χ2 = 5.19, p = 0.02
Eyes water in house (from smoke)
  
No§
1.0
 
Yes/(More than 5 Years)
1.27 (0.92–1.75)
0.14
Test of Homogeneity
 
χ2 = 2.16, p = 0.14
Marital status
  
Single§
1.0
 
Married
1.20 (0.77–1.85)
0.42
Widowed
1.52 (0.89–2.59)
0.13
Separated/Divorced
2.73 (1.41–5.28)
0.003
Test of Homogeneity (3df)
 
χ2 = 10.31, p = 0.02
Consumption of maize beer
  
Never§
1.0
 
Less than 1× week
0.74 (0.38–1.42)
0.36
More than 1× week
4.16 (1.26–13.80)
0.02
Most Days
2.18 (0.79–6.04)
0.13
Test for Trend
 
χ2 = 3.72, p = 0.05
Consumption of homemade spirits
  
Never§
1.0
 
Less than 1× week
2.16 (0.93–5.03)
0.07
More than 1× week
1.00 (.20–5.05)
0.99
Most Days
1.68 (0.72–3.92)
0.23
Test for Trend
 
χ2 = 2.25, p = 0.13
All values were calculated with the χ2 test with 1df unless noted otherwise. In the multivariate model, all bivariately statistically significant variables at p = 0.1 are included and odds ratios are also adjusted for sex. Each variable was adjusted for all other variables in the table. The Hosmer-Lemeshow goodness-of-fit statistic = 5.66 with 8 df (p = 0.69). § These patients served as the reference group

Discussion

The primary aim of this study was to identify risk factors for high HHV-8 titers in HIV-seronegative, black South African adults as means to identify potential co-factors in the development of Kaposi's sarcoma. Studies have found that the risk of KS is increased with increasing anti-HHV-8 titers [13, 14]. Similarly, high anti-HHV-8 titers have been correlated with high HHV-8 viral load, as it is believed that the titer of antibodies against HHV-8 reflects viral load [16]. As has been described by Sitas et al., 1999, the relationship between high anti-HHV-8 titers and KS may be similar to the relationship between EBV and African Burkitt's lymphoma [28] and nasopharyngeal cancer [29]. For these two cancers, high antibody titers correlate well with the risk of disease.
In addition to HIV infection, which dramatically increases risk for KS, which has been well described, the discrepancy between the geographical distribution of KS both prior to and with the AIDS epidemic suggests the presence of an additional co-factor in the development of this malignancy [7, 30]. As Dedicoat and Newton note, HHV-8 is common in Botswana (76–87% seroprevalence) and the Gambia (29–84% seroprevalence) but KS was rare in these areas prior to the HIV epidemic. Among the community of approximately 45,000 Ethiopian Jews in Israel, HHV-8 seroprevalence is between 39–57%, however, there has been only one case of KS documented from 1982 to 1998 [8].
We examined approximately 50 potential risk factors in relation to high anti-HHV-8 titers. In our final analysis, only those factors that were significant at the 1% level were considered in the multivariate model. Risk factors that were significant for high anti-HHV-8 titers included older age and socioeconomic variables. The associations we found between age and increased risk for high HHV-8 titers concur with results from other studies [18, 31]. In contrast with the findings of Plaincoulaine et al. 2002, however, we found no greater risk for high HHV-8 titers in males than females. Looking at a subset of our sample above age 65, we also found no greater risk for males than females with high titers being 43.9% (68/155) in men and 42.9% (54/126) in women (χ2 (1df) = 0.28, p = 0.59). Other studies have found that the incidence of KS is higher in males than females in endemic areas such as sub-Saharan Africa and the Mediterranean region [10, 32, 33]. As we found no difference between males and female in risk for high anti-HHV-8 titers, to explain this discrepancy, there may be additional risk factors for the development of KS.
Increasing titers associated with increasing age may be related to the natural aging process or may be a marker for length of infection as suggested by other studies [17]. It is difficult to speculate about length of infection with this cross-sectional, prevalence data. Risk factors for high titers potentially include sexual risk factors. Although we did not find any associations between lifetime number of sexual partners and high anti-HHV-8 antibody titers, we did find an association between being separated/divorced and increased risk for high anti-HHV-8 antibody titers. Being separated or divorced could be a proxy for having more sexual partners, particularly for women, who may find themselves impoverished after divorce and in need of engaging in survival sex or sex work. Alternatively, being divorced or separated may suggest low socioeconomic status.
High HHV-8 titers were associated with variables measuring socioeconomic status. Using electricity 20 years ago was protective. Electricity was used by a fraction of the urban and rural black South African population 20 years ago and was a good marker of socioeconomic status at that time. In our study, only 11.7% (257/2191) had access to electricity 20 years ago. This contrasts with the almost universal access to electricity in urban areas of Gauteng province (the province where 76.6% (1681/2191) of the sample lives) as reported in the 1996 census [34]. Having been born in an urban area was marginally associated with increased risk (p = 0.08) as was using cheaper, non-brick building materials such as tin, mud or wood for home construction (p = 0.09). Crowding may be more of a problem in urban areas and in poorer households and could be a risk factor for high titers. Research has indicated that stressors can increase EBV antibody titers through the steady-state expression of latent herpes viruses [35, 36]; it is possible that stressors correlated with low SES may account for an increase in anti-HHV8 titers. However, high anti-HHV-8 antibody titers may also be a marker of length of infection [17] particularly as those who were living in a higher SES environment 20 years ago are protected against having high HHV-8 titers. As this study is based on prevalent HHV-8 infection, we can only hypothesize about the timing and length of infection in relation to risk for high anti-HHV-8 antibody titers.
Interestingly, an association with the consumption of maize beer was a significant risk factor for high titers. Given the association between consumption of traditionally brewed alcoholic beverages and high serum ferritin iron concentrations in black South Africans [37, 38], consumption of traditional beers may facilitate the development of Kaposi's sarcoma. It has been reported that traditional beers have high concentrations of ionized, bio-available iron (between 82.0 mg/l) as a result of being brewed and fermented in iron-clad pots [39, 40]. Ziegler et al. has reported that there may be an association between exposure to the iron-rich soils of East and Central Africa and the development of KS [12]. In a case-control study of KS in HIV positive Ugandan patients, Ziegler et al. found that those who drank home-made beer less than once a week had an OR of 2.65 95%CI (1.9–3.8) although there was no trend in risk with increased consumption [11]. Our association with maize beer, however, could be a chance finding since approximately 50 significance tests were performed. Unlike the protective association found between smoking and decreased KS risk by Goedert et al. [41], we found no association between smoking and high anti-HHV-8 antibody titers.
As this case control study was based on prevalent HHV-8 infection, it is important to emphasize the limitations of using this type of data. We were unable to establish a temporal relationship between high anti-HHV-8 antibody titers and the multitude of predictors evaluated in this study. Additionally, as some of our conclusions differ from studies that have evaluated risk factors for KS, there may be different risk factors for KS and anti-HHV-8 antibody titers that should be evaluated in future studies.

Conclusion

The associations we found between age, socioeconomic status and consumption of traditionally brewed alcoholic beverages and high anti-HHV-8 titers need to be examined in a prospective study. If there is an association between the development of KS and consumption of traditionally brewed beers due to the high levels of bio-available iron in these beers, public health campaigns could be directed at the replacement of iron containers with earthenware pots [42]. Additionally, specifics of the low socioeconomic environment that may increase risk for high anti-HHV-8 antibody titers such as crowding need to be examined in prospective study.

List of abreviations

HHV-8: Human herpesvirus 8.
KS: Kaposi's sarcoma

Author's contributions

FS conceived of the study, participated in its design, coordination and supervised the statistical analysis. JW was involved in the design of the study and performed the statistical analysis. RN was involved in the design of the study and supervised the statistical analysis. MU and LS were involved in the design of the study. MP, PR and RS supplied patients for this study. MH provided pathology reports and participated in the study design. DB performed the immunofluorescence assays. All authors read and approved the final manuscript.

Acknowledgements

The authors would like to acknowledge the support of the Johannesburg, Chris Hani Baragwanath and Hillbrow Hopsitals.

List of competing interests

None declared.
Literatur
1.
Zurück zum Zitat Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994, 266: 1865-9.CrossRefPubMed Chang Y, Cesarman E, Pessin MS, Lee F, Culpepper J, Knowles DM, Moore PS: Identification of Herpesvirus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science. 1994, 266: 1865-9.CrossRefPubMed
2.
Zurück zum Zitat Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS: KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996, 2: 925-8.CrossRefPubMed Gao SJ, Kingsley L, Li M, Zheng W, Parravicini C, Ziegler J, Newton R, Rinaldo CR, Saah A, Phair J, Detels R, Chang Y, Moore PS: KSHV antibodies among Americans, Italians and Ugandans with and without Kaposi's sarcoma. Nat Med. 1996, 2: 925-8.CrossRefPubMed
3.
Zurück zum Zitat Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FEA, Aldam DM, Denton AS, Miller RF, Weller IVD, Weiss RA, Tedder RS, Schulz TF: Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet. 1995, 346: 799-802. 10.1016/S0140-6736(95)91619-9.CrossRefPubMed Whitby D, Howard MR, Tenant-Flowers M, Brink NS, Copas A, Boshoff C, Hatzioannou T, Suggett FEA, Aldam DM, Denton AS, Miller RF, Weller IVD, Weiss RA, Tedder RS, Schulz TF: Detection of Kaposi's sarcoma associated herpesvirus in peripheral blood of HIV-infected individuals and progression to Kaposi's sarcoma. Lancet. 1995, 346: 799-802. 10.1016/S0140-6736(95)91619-9.CrossRefPubMed
4.
Zurück zum Zitat Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, Weiss RA, O'Leary JJ: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med. 1995, 1: 1274-8.CrossRefPubMed Boshoff C, Schulz TF, Kennedy MM, Graham AK, Fisher C, Thomas A, McGee JO, Weiss RA, O'Leary JJ: Kaposi's sarcoma-associated herpesvirus infects endothelial and spindle cells. Nat Med. 1995, 1: 1274-8.CrossRefPubMed
5.
Zurück zum Zitat Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT: Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997, 71: 715-9.PubMedPubMedCentral Staskus KA, Zhong W, Gebhard K, Herndier B, Wang H, Renne R, Beneke J, Pudney J, Anderson DJ, Ganem D, Haase AT: Kaposi's sarcoma-associated herpesvirus gene expression in endothelial (spindle) tumor cells. J Virol. 1997, 71: 715-9.PubMedPubMedCentral
6.
Zurück zum Zitat Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, Hoover DR, Parry JP, Conley LJ, Jaffe HW, Chang Y: Kaposi's sarcoma-associated herpesviurs infection prior to onset of Kaposi's sarcoma. AIDS. 1996, 10: 175-180.CrossRefPubMed Moore PS, Kingsley LA, Holmberg SD, Spira T, Gupta P, Hoover DR, Parry JP, Conley LJ, Jaffe HW, Chang Y: Kaposi's sarcoma-associated herpesviurs infection prior to onset of Kaposi's sarcoma. AIDS. 1996, 10: 175-180.CrossRefPubMed
7.
Zurück zum Zitat Dedicoat M, Newton R: Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. British Journal of Cancer. 2003, 88: 1-3. 10.1038/sj.bjc.6600745.CrossRefPubMedPubMedCentral Dedicoat M, Newton R: Review of the distribution of Kaposi's sarcoma-associated herpesvirus (KSHV) in Africa in relation to the incidence of Kaposi's sarcoma. British Journal of Cancer. 2003, 88: 1-3. 10.1038/sj.bjc.6600745.CrossRefPubMedPubMedCentral
8.
Zurück zum Zitat Grossman Z, Iscovich J, Schwartz F, Azizi E, Klepfish A, Schattner A, Sarid R: Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc. 2002, 77 (9): 905-9.CrossRefPubMed Grossman Z, Iscovich J, Schwartz F, Azizi E, Klepfish A, Schattner A, Sarid R: Absence of Kaposi sarcoma among Ethiopian immigrants to Israel despite high seroprevalence of human herpesvirus 8. Mayo Clin Proc. 2002, 77 (9): 905-9.CrossRefPubMed
9.
Zurück zum Zitat Greenblatt R: Kaposi's sarcoma and human herpesvirus-8. Infect Dis Clin North Am. 1998, 12 (1): 63-82.CrossRefPubMed Greenblatt R: Kaposi's sarcoma and human herpesvirus-8. Infect Dis Clin North Am. 1998, 12 (1): 63-82.CrossRefPubMed
10.
Zurück zum Zitat Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R: Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000, 88 (3): 500-17. 10.1002/(SICI)1097-0142(20000201)88:3<500::AID-CNCR3>3.3.CO;2-0.CrossRefPubMed Iscovich J, Boffetta P, Franceschi S, Azizi E, Sarid R: Classic Kaposi sarcoma: epidemiology and risk factors. Cancer. 2000, 88 (3): 500-17. 10.1002/(SICI)1097-0142(20000201)88:3<500::AID-CNCR3>3.3.CO;2-0.CrossRefPubMed
11.
Zurück zum Zitat Ziegler JL, Newton R, Katongole-Mbidde E, Mbulataiye S, De Cock K, Wabinga H, Mugerwa J, Katabira E, Jaffe H, Parkin DM, Reeves G, Weiss R, Beral V: Risk factors for Kaposi's sarcoma in HIV-positive subjects in Uganda. AIDS. 1997, 11: 1619-1626. 10.1097/00002030-199713000-00011.CrossRefPubMed Ziegler JL, Newton R, Katongole-Mbidde E, Mbulataiye S, De Cock K, Wabinga H, Mugerwa J, Katabira E, Jaffe H, Parkin DM, Reeves G, Weiss R, Beral V: Risk factors for Kaposi's sarcoma in HIV-positive subjects in Uganda. AIDS. 1997, 11: 1619-1626. 10.1097/00002030-199713000-00011.CrossRefPubMed
12.
Zurück zum Zitat Ziegler JL, Simonart T, Snoeck R: Kaposi's saroma, oncogenic viruses and iron. Journal of Clinical Virology. 2001, 20: 127-130. 10.1016/S1386-6532(00)00137-2.CrossRefPubMed Ziegler JL, Simonart T, Snoeck R: Kaposi's saroma, oncogenic viruses and iron. Journal of Clinical Virology. 2001, 20: 127-130. 10.1016/S1386-6532(00)00137-2.CrossRefPubMed
13.
Zurück zum Zitat Ziegler J, Newton R, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C, Uganda Kaposi's Sarcoma Study Group: Risk factors for Kaposi's sarcoma: A Case-control study of HIV-seronegative people in Uganda. International Journal of Cancer. 2003, 103: 233-240. 10.1002/ijc.10818.CrossRefPubMed Ziegler J, Newton R, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C, Uganda Kaposi's Sarcoma Study Group: Risk factors for Kaposi's sarcoma: A Case-control study of HIV-seronegative people in Uganda. International Journal of Cancer. 2003, 103: 233-240. 10.1002/ijc.10818.CrossRefPubMed
14.
Zurück zum Zitat Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, Jentsch U, Pacella-Norman R, Bourboulia D, Whitby D, Boshoff C, Weiss R: Antibodies against human herpesviurs 8 in black South African patients with cancer. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med. 1999, 340 (24): 1863-71. 10.1056/NEJM199906173402403.CrossRefPubMed Sitas F, Carrara H, Beral V, Newton R, Reeves G, Bull D, Jentsch U, Pacella-Norman R, Bourboulia D, Whitby D, Boshoff C, Weiss R: Antibodies against human herpesviurs 8 in black South African patients with cancer. Antibodies against human herpesvirus 8 in black South African patients with cancer. N Engl J Med. 1999, 340 (24): 1863-71. 10.1056/NEJM199906173402403.CrossRefPubMed
15.
Zurück zum Zitat Rezza G, Andreoni M, Dorrucci M, Pezzotti P, Monini P, Zerboni R, Salassa B, Colangeli V, Sarmati L, Nicastri E, Barbanera M, Pristera R, Aiuti F, Ortona L, Ensoli B: Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst. 1999, 91 (17): 1468-74. 10.1093/jnci/91.17.1468.CrossRefPubMed Rezza G, Andreoni M, Dorrucci M, Pezzotti P, Monini P, Zerboni R, Salassa B, Colangeli V, Sarmati L, Nicastri E, Barbanera M, Pristera R, Aiuti F, Ortona L, Ensoli B: Human herpesvirus 8 seropositivity and risk of Kaposi's sarcoma and other acquired immunodeficiency syndrome-related diseases. J Natl Cancer Inst. 1999, 91 (17): 1468-74. 10.1093/jnci/91.17.1468.CrossRefPubMed
16.
Zurück zum Zitat Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J: Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol. 2001, 39 (12): 4269-73. 10.1128/JCM.39.12.4269-4273.2001.CrossRefPubMedPubMedCentral Tedeschi R, Enbom M, Bidoli E, Linde A, De Paoli P, Dillner J: Viral load of human herpesvirus 8 in peripheral blood of human immunodeficiency virus-infected patients with Kaposi's sarcoma. J Clin Microbiol. 2001, 39 (12): 4269-73. 10.1128/JCM.39.12.4269-4273.2001.CrossRefPubMedPubMedCentral
17.
Zurück zum Zitat Biggar RJ, Engels EA, Whitby D, Kedes DH, Goedert JJ: Antibody Reactivity to Latent and Lytic Antigens to Human Hepesvirus-8 in Longitudinally Followed Homosexual Men. Journal of Infectious Disease. 2003, 187: 1218-CrossRef Biggar RJ, Engels EA, Whitby D, Kedes DH, Goedert JJ: Antibody Reactivity to Latent and Lytic Antigens to Human Hepesvirus-8 in Longitudinally Followed Homosexual Men. Journal of Infectious Disease. 2003, 187: 1218-CrossRef
18.
Zurück zum Zitat Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C, Uganda Kaposi's Sarcoma Study Group: The seroepidemiology of Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. International Journal of Cancer. 2003, 103: 226-232. 10.1002/ijc.10817.CrossRefPubMed Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C, Uganda Kaposi's Sarcoma Study Group: The seroepidemiology of Kaposi's-sarcoma-associated herpesvirus (KSHV/HHV-8) in adults with cancer in Uganda. International Journal of Cancer. 2003, 103: 226-232. 10.1002/ijc.10817.CrossRefPubMed
19.
Zurück zum Zitat Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C, Uganda Kaposi's Sarcoma Study Group: Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998, 91: 1671-9. Newton R, Ziegler J, Bourboulia D, Casabonne D, Beral V, Mbidde E, Carpenter L, Reeves G, Parkin DM, Wabinga H, Mbulaiteye S, Jaffe H, Weiss R, Boshoff C, Uganda Kaposi's Sarcoma Study Group: Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998, 91: 1671-9.
20.
Zurück zum Zitat Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, Howard MR, Gao SJ, Bohenzky RA, Simmonds P, Lee C, de Ruiter A, Hatzakis A, Tedder RS, Weller IV, Weiss RA, Moore PS: Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996, 348: 1133-8. 10.1016/S0140-6736(96)07560-5.CrossRefPubMed Simpson GR, Schulz TF, Whitby D, Cook PM, Boshoff C, Rainbow L, Howard MR, Gao SJ, Bohenzky RA, Simmonds P, Lee C, de Ruiter A, Hatzakis A, Tedder RS, Weller IV, Weiss RA, Moore PS: Prevalence of Kaposi's sarcoma associated herpesvirus infection measured by antibodies to recombinant capsid protein and latent immunofluorescence antigen. Lancet. 1996, 348: 1133-8. 10.1016/S0140-6736(96)07560-5.CrossRefPubMed
21.
Zurück zum Zitat Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D: The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996, 2: 918-924. [Erratum, Nat Med 1996; 2: 1041]CrossRefPubMed Kedes DH, Operskalski E, Busch M, Kohn R, Flood J, Ganem D: The seroepidemiology of human herpesvirus 8 (Kaposi's sarcoma-associated herpesvirus): distribution of infection in KS risk groups and evidence for sexual transmission. Nat Med. 1996, 2: 918-924. [Erratum, Nat Med 1996; 2: 1041]CrossRefPubMed
22.
Zurück zum Zitat Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, Herrington CS, Moore PS, Schulz TF: The 222 to 234-kilodalton laten nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virology. 1997, 71: 5915-5921.PubMedPubMedCentral Rainbow L, Platt GM, Simpson GR, Sarid R, Gao SJ, Stoiber H, Herrington CS, Moore PS, Schulz TF: The 222 to 234-kilodalton laten nuclear protein (LNA) of Kaposi's sarcoma-associated herpesvirus (human herpesvirus 8) is encoded by orf73 and is a component of the latency-associated nuclear antigen. J Virology. 1997, 71: 5915-5921.PubMedPubMedCentral
23.
Zurück zum Zitat Kellam P, Boshoff C, Whitby D, Matthews S, Weiss RA, Talbot SJ: Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virology. 1997, 1: 19-29. Kellam P, Boshoff C, Whitby D, Matthews S, Weiss RA, Talbot SJ: Identification of a major latent nuclear antigen, LNA-1, in the human herpesvirus 8 genome. J Hum Virology. 1997, 1: 19-29.
24.
Zurück zum Zitat Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, Coignet L, Warnke RA, Strauchen JA, Matutes E, Kamel OW, Moore PS, Weiss RA, Chang Y: Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998, 91: 1671-1679.PubMed Boshoff C, Gao SJ, Healy LE, Matthews S, Thomas AJ, Coignet L, Warnke RA, Strauchen JA, Matutes E, Kamel OW, Moore PS, Weiss RA, Chang Y: Establishing a KSHV+ cell line (BCP-1) from peripheral blood and characterizing its growth in Nod/SCID mice. Blood. 1998, 91: 1671-1679.PubMed
25.
Zurück zum Zitat Renwick H, Halaby T, Weverling GJ, Dukers NH, Simpson GR, Coutinho RA, Lange JM, Schulz TF, Goudsmit J: Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS. 1998, 12 (18): 2481-8. 10.1097/00002030-199818000-00018.CrossRefPubMed Renwick H, Halaby T, Weverling GJ, Dukers NH, Simpson GR, Coutinho RA, Lange JM, Schulz TF, Goudsmit J: Seroconversion for human herpesvirus 8 during HIV infection is highly predictive of Kaposi's sarcoma. AIDS. 1998, 12 (18): 2481-8. 10.1097/00002030-199818000-00018.CrossRefPubMed
26.
Zurück zum Zitat STATA: Stata software. College Park, TX: STATA. 2001 STATA: Stata software. College Park, TX: STATA. 2001
27.
Zurück zum Zitat Lemeshow S, Hosmer DW: A Review of goodness of fit statistics for use in the development of logistic regression models. American Journal of Epidemiology. 1982, 115: 92-106.PubMed Lemeshow S, Hosmer DW: A Review of goodness of fit statistics for use in the development of logistic regression models. American Journal of Epidemiology. 1982, 115: 92-106.PubMed
28.
Zurück zum Zitat de-The G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W: Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978, 274: 756-61.CrossRefPubMed de-The G, Geser A, Day NE, Tukei PM, Williams EH, Beri DP, Smith PG, Dean AG, Bronkamm GW, Feorino P, Henle W: Epidemiological evidence for causal relationship between Epstein-Barr virus and Burkitt's lymphoma from Ugandan prospective study. Nature. 1978, 274: 756-61.CrossRefPubMed
29.
Zurück zum Zitat de-The G, Lavoue MF, Muenz L: Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas. In: Nasopharyngeal carcinoma: etiology and control. Edited by: de-The, Ito Y. 1978, Lyons, France: International Agency for Research on Cancer, (IARC scientific publications no.20.) de-The G, Lavoue MF, Muenz L: Differences in EBV antibody titres of patients with nasopharyngeal carcinoma originating from high, intermediate and low incidence areas. In: Nasopharyngeal carcinoma: etiology and control. Edited by: de-The, Ito Y. 1978, Lyons, France: International Agency for Research on Cancer, (IARC scientific publications no.20.)
30.
Zurück zum Zitat Cook-Mozaffari P, Newton R, Beral V, Burkitt DP: The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998, 78: 1521-8.CrossRefPubMedPubMedCentral Cook-Mozaffari P, Newton R, Beral V, Burkitt DP: The geographical distribution of Kaposi's sarcoma and of lymphomas in Africa before the AIDS epidemic. Br J Cancer. 1998, 78: 1521-8.CrossRefPubMedPubMedCentral
31.
Zurück zum Zitat Plancoulaine S, Abel L, van Beveren M, Gessain A: High titers of anti-human herpesvirus 8 antibodies in elderly males in an endemic population. Journal of the National Cancer Institute. 2002, 94 (7): 133-5. Plancoulaine S, Abel L, van Beveren M, Gessain A: High titers of anti-human herpesvirus 8 antibodies in elderly males in an endemic population. Journal of the National Cancer Institute. 2002, 94 (7): 133-5.
32.
Zurück zum Zitat Vitale F, Briffa DV, Whitby D, Maida I, Grochowska A, Levin A, Romano N, Goedert JJ: Annual Incidence Rates of Classical KS in 3 Mediterranean Islands. Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. International Journal of Cancer. 2001, 91: 588-591. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1089>3.0.CO;2-8.CrossRefPubMed Vitale F, Briffa DV, Whitby D, Maida I, Grochowska A, Levin A, Romano N, Goedert JJ: Annual Incidence Rates of Classical KS in 3 Mediterranean Islands. Kaposi's sarcoma herpes virus and Kaposi's sarcoma in the elderly populations of 3 Mediterranean islands. International Journal of Cancer. 2001, 91: 588-591. 10.1002/1097-0215(200002)9999:9999<::AID-IJC1089>3.0.CO;2-8.CrossRefPubMed
33.
Zurück zum Zitat Serraino D, Corona RM, Giuliani M, Farchi F, Sarmati L, Uccella I, et al: Infection with Human Herpesvirus Type 8 and Kaposi's Sarcoma in a Central Italian Area Formerly Endemic for Malaria. Infection. 2003, 31 (1): 47-50.CrossRefPubMed Serraino D, Corona RM, Giuliani M, Farchi F, Sarmati L, Uccella I, et al: Infection with Human Herpesvirus Type 8 and Kaposi's Sarcoma in a Central Italian Area Formerly Endemic for Malaria. Infection. 2003, 31 (1): 47-50.CrossRefPubMed
34.
Zurück zum Zitat Statistics South Africa: Census in Brief. Pretoria: Statistics – SA. 1996 Statistics South Africa: Census in Brief. Pretoria: Statistics – SA. 1996
35.
Zurück zum Zitat Stowe RP, Pierson DL, Feeback DL, Barrett AD: Stress-induced reactivation of Epstein-Barr virus in astronauts. Neuroimmunomodulation. 2000, 8 (2): 51-8. 10.1159/000026453.CrossRefPubMed Stowe RP, Pierson DL, Feeback DL, Barrett AD: Stress-induced reactivation of Epstein-Barr virus in astronauts. Neuroimmunomodulation. 2000, 8 (2): 51-8. 10.1159/000026453.CrossRefPubMed
36.
Zurück zum Zitat Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001, 15 (3): 199-226. 10.1006/brbi.2000.0597.CrossRefPubMed Zorrilla EP, Luborsky L, McKay JR, Rosenthal R, Houldin A, Tax A, McCorkle R, Seligman DA, Schmidt K: The relationship of depression and stressors to immunological assays: a meta-analytic review. Brain Behav Immun. 2001, 15 (3): 199-226. 10.1006/brbi.2000.0597.CrossRefPubMed
37.
Zurück zum Zitat Gordeuk VR, Brittenham GML: Iron overload – still a problem among the Zulus. South African Medical Journal. 1986, 603-4. Gordeuk VR, Brittenham GML: Iron overload – still a problem among the Zulus. South African Medical Journal. 1986, 603-4.
38.
Zurück zum Zitat Bothwell TH, Seftel H, Jacobs P, Torrance JD, Baumslag N: Iron overload in Bantu subjects. American Journal of Clinical Nutrition. 1964, 14: 47-51.PubMed Bothwell TH, Seftel H, Jacobs P, Torrance JD, Baumslag N: Iron overload in Bantu subjects. American Journal of Clinical Nutrition. 1964, 14: 47-51.PubMed
39.
Zurück zum Zitat Baker LD: Alcohol consumption among South African blacks and its relationship to iron overload. South African Medical Journal. 1986, 70: 160-2.PubMed Baker LD: Alcohol consumption among South African blacks and its relationship to iron overload. South African Medical Journal. 1986, 70: 160-2.PubMed
40.
Zurück zum Zitat Bothwell TH, Charlton RW, Sewftel HC: Oral iron overload. South African Medical Journal. 1965, 892-900. Bothwell TH, Charlton RW, Sewftel HC: Oral iron overload. South African Medical Journal. 1965, 892-900.
41.
Zurück zum Zitat Goedert JJ, Vitale F, Lauria C, Serraino D, Tamburini M, Montella M, Messina A, Brown EE, Rezza G, Gafa L, Romano N, Classical Kaposi's Sarcoma Working Group: Risk factors for classical Kaposi's sarcoma. Journal of the National Cancer Institute. 2002, 94 (22): 1712-8. 10.1093/jnci/94.22.1712.CrossRefPubMed Goedert JJ, Vitale F, Lauria C, Serraino D, Tamburini M, Montella M, Messina A, Brown EE, Rezza G, Gafa L, Romano N, Classical Kaposi's Sarcoma Working Group: Risk factors for classical Kaposi's sarcoma. Journal of the National Cancer Institute. 2002, 94 (22): 1712-8. 10.1093/jnci/94.22.1712.CrossRefPubMed
42.
Zurück zum Zitat Friedman BM, Baynes RD, Bothwell TH, Gordeuk VR, Macfarlane BJ, Lamparelli RD, Robinson EJ, Sher R, Hamberg S: Dietary iron overload in southern African rural blacks. South African Medical Journal. 1990, 78: 301-5.PubMed Friedman BM, Baynes RD, Bothwell TH, Gordeuk VR, Macfarlane BJ, Lamparelli RD, Robinson EJ, Sher R, Hamberg S: Dietary iron overload in southern African rural blacks. South African Medical Journal. 1990, 78: 301-5.PubMed
Metadaten
Titel
Risk factors for high anti-HHV-8 antibody titers (≥1:51,200) in black, HIV-1 negative South African cancer patients: a case control study
verfasst von
Janet M Wojcicki
Rob Newton
Margaret I Urban
Lara Stein
Martin Hale
Moosa Patel
Paul Ruff
Ranjan Sur
Dimitra Bourboulia
Freddy Sitas
Publikationsdatum
01.12.2003
Verlag
BioMed Central
Erschienen in
BMC Infectious Diseases / Ausgabe 1/2003
Elektronische ISSN: 1471-2334
DOI
https://doi.org/10.1186/1471-2334-3-21

Weitere Artikel der Ausgabe 1/2003

BMC Infectious Diseases 1/2003 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Notfall-TEP der Hüfte ist auch bei 90-Jährigen machbar

26.04.2024 Hüft-TEP Nachrichten

Ob bei einer Notfalloperation nach Schenkelhalsfraktur eine Hemiarthroplastik oder eine totale Endoprothese (TEP) eingebaut wird, sollte nicht allein vom Alter der Patientinnen und Patienten abhängen. Auch über 90-Jährige können von der TEP profitieren.

Niedriger diastolischer Blutdruck erhöht Risiko für schwere kardiovaskuläre Komplikationen

25.04.2024 Hypotonie Nachrichten

Wenn unter einer medikamentösen Hochdrucktherapie der diastolische Blutdruck in den Keller geht, steigt das Risiko für schwere kardiovaskuläre Ereignisse: Darauf deutet eine Sekundäranalyse der SPRINT-Studie hin.

Bei schweren Reaktionen auf Insektenstiche empfiehlt sich eine spezifische Immuntherapie

Insektenstiche sind bei Erwachsenen die häufigsten Auslöser einer Anaphylaxie. Einen wirksamen Schutz vor schweren anaphylaktischen Reaktionen bietet die allergenspezifische Immuntherapie. Jedoch kommt sie noch viel zu selten zum Einsatz.

Therapiestart mit Blutdrucksenkern erhöht Frakturrisiko

25.04.2024 Hypertonie Nachrichten

Beginnen ältere Männer im Pflegeheim eine Antihypertensiva-Therapie, dann ist die Frakturrate in den folgenden 30 Tagen mehr als verdoppelt. Besonders häufig stürzen Demenzkranke und Männer, die erstmals Blutdrucksenker nehmen. Dafür spricht eine Analyse unter US-Veteranen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.